kallyope glp-1 program Pipeline The weight-loss-independent hepatoprotective benefits of

Health literacy and cardiovascular disease: fundamental relevance to primary and secondary prevention: a scientific statement from the American Heart Association

1 and S8)

Safety needles have an additional plastic canister to help prevent needlesstick injuries and reuse of needles

Novel biased GLP1 agonists described in the preclinical literature The first bespoke biased GLP1 agonist to be reported, P5, was obtained through an innovative strategy involving expression of single peptide sequences from an exendin4derived combinatorial peptide library, with peptides anchored to the cell surface via a flexible linker that allows autocrine activation of GLP1 receptors expressed in the same cell (Zhang et al., 2015)

Keywords: costeffectiveness, GIP, GLP1, pharmacodynamics, pharmacokinetics, semaglutide 1